Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: A 16-week bromocriptine controlled study

Journal of Neurology

Volumn 250, Issue 1, 2003, Pages 90-96

  Im, Joo Hyuk ^a   Ha, Jeong Ho ^a   Cho, In Sook ^a   Lee, Myoung C ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Bromocriptine; Motor fluctuations; Parkinson's disease; Ropinirole

Indexed keywords

BROMOCRIPTINE; LEVODOPA; LISURIDE; PERGOLIDE; ROPINIROLE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FACE EDEMA; FEMALE; FLUSHING; HALLUCINATION; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RATING SCALE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SWEATING; TASTE DISORDER; THORAX PAIN; TINNITUS; VERTIGO; VISUAL DISORDER; VIVID DREAM; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; BROMOCRIPTINE; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; INDOLES; LEVODOPA; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 0037279113     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0937-z     Document Type: Article

References (23)

1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF, for the Ropinirole Study Group (1997) Ropinirole for the treatment of early Parkinson's disease. Neurology 49: 393-399
2. Brooks DJ, Turjanski N, Burn DJ (1995) Ropinirole in the symptomatic treatment of Parkinson's disease. J Neural Transm 45(suppl):231-238
3. Cotzias GC, Papavasiliou PS, Gellene R (1969) Modification of parkinsonism: chronic treatment of L-dopa. N Engl J Med 280:337-345
4. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374-379
5. Fahn S, Elton R, UPDRS development Committee (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne D (eds) Recent developments in Parkinson's disease. Vol 2. MacMillan, New York, pp 153-163
6. Ferreira JJ, Galitzky M, Montastruc JL, Rascol O (2000) Sleep attacks and Parkinson's disease treatment. Lancet 355:1333-1334
7. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52:1908-1910
8. Hoehn MM (2000) Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole. Neurology 54:275
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
10. Jankovic J, Marsden CD (1988) Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Urban and Schwarzenberg, Baltimore-Munich, pp 283-314
11. Kapoor R, Pirtosek Z, Frankel JD, Stern GM, Lees AJ, Bottomley JM, Sree Haran N (1989) Treatment of Parkinson's disease with novel dopamine D2 agonist SK&F 101468. Lancet 1:1445-1446
12. Kleedorfer B, Stern GM, Lees AJ, Bottomley JM, Sree Haran N (1991) Ropinirole (SK&F 101468) in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 54:938
13. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S, for the 053 Study Group (1999) A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 53:364-370 WITH Neurology 53:1162 (erratum)
14. Lieberman A (1992) Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline. Neurology 42(suppl 4):37-40
15. Lieberman AN, Neophytides A, Leibowitz M, Gopinathan G, Pact V, Walker R, Goodgold A, Goldstein M (1983) Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease. Adv Neurol 37:95-108
16. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S, Hurtig H, Yahr M, and the Ropinirole Study Group (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51: 1057-1062
17. Quinn N (1990) The modern management of Parkinson's disease. J Neurol Neurosurg Psychiatry 53:93-95
18. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, for the 056 Study Group (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342:1484-1491
19. Rascol O, Lees AJ, Senard JM, Pirotosek Z, Brefel C, Montastruc JH, Fuell D (1996) A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. Adv Neurol 69:531-534
20. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D (1996). Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 19:234-245
21. Ropinirole 043 study group (1996) A double-blind comparative study of ropinirole vs. bromocriptine in the treatment of parkinsonian patients not optimally controlled on levodopa. Mov Disord 11(suppl 1):188
22. Schapira AHV (2000) Sleep attacks (sleep episodes) with pergolide. Lancet 355:1332-1333
23. Sethi KD, O'Brien CF, Hammerstad JP, Adler CH, Davis TL, Taylor RL, Sanchez-Ramos J, Bertoni JM, Hauser RA for the Ropinirole Study Group (1998) Ropinirole for the treatment of early Parkinson's disease: a 12-month experience. Arch Neurol 55:1211-1216